American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting

Viewing 1-20 of 54 articles

ASTRO 2022: Prognostic and Predictive Performance of a 24-Gene Post-Operative Radiation Therapy Outcomes Score (PORTOS) in a Phase 3 Randomized Trial of Dose-Intensified Salvage Radiotherapy after Radical Prostatectomy (SAKK 09/10)

ASTRO 2022: MRI-Guided vs. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE): Primary Endpoint Analysis of a Phase III Randomized Trial

ASTRO 2022: Toxicity and Patient Reported Quality of Life Outcomes Following Prostate SBRT with Focal Boost to MRI Identified Prostate Cancer Lesions: Results of a Phase II Trial

ASTRO 2022: Patient Reported Quality of Life after Moderately Hypofractionated Proton Beam Therapy

ASTRO 2022: Superior Post-Treatment Biopsy Outcomes with High Dose SBRT Compared to High-Dose Conventionally Fractionated IMRT for Clinically Localized Prostate Cancer

ASTRO 2022: Transcriptomic Analysis of ATM Expression in Localized Prostate Cancer – Implications for Radiotherapy Treatment

ASTRO 2022: INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients

ASTRO 2022: Bladder Only versus Bladder Plus Pelvic Lymph Node Chemoradiation for Muscle-Invasive Bladder Cancer

ASTRO 2022: Long-Term Outcomes of Stereotactic Ablative Body Radiotherapy to Primary Renal Cell Carcinoma: A Multicenter Analysis from IROCK - The International Radiosurgery Oncology Consortium for Kidney

ASTRO 2022: Clinical Outcomes in cN+M0 Bladder Cancer Patients: Can the Bladder be Spared?

ASTRO 2022: Multi-Institutional Matched Comparison of Radical Cystectomy to Trimodality Therapy for Muscle Invasive Bladder Cancer

ASTRO 2022: Challenging Cases in Bladder Cancer: Node-positive and Oligometastatic Disease

ASTRO 2022: Challenging Cases for Bladder Cancer: Treatment Planning and Technique

ASTRO 2022: Optimal Duration of ADT with Definitive Radiotherapy for Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis from the International MARCAP Consortium

ASTRO 2022: Predictive Value of Ga68-PSMA PETCT-Based Response to Neoadjuvant Androgen Deprivation Therapy in Node Positive Prostate Cancer Treated with Radical Radiotherapy

ASTRO 2022: Phase III Trial of Dose Escalated Radiation Therapy and Standard ADT vs. Dose Escalated Radiation Therapy and Enhanced ADT with TAK-700 for Men with High Risk Prostate Cancer (NRG Oncology/RTOG 1115)

ASTRO 2022: Sequencing of Androgen Deprivation Therapy of Short Duration with Radiotherapy for Non-Metastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials

ASTRO 2022: Association of Prostate-Specific Antigen Screening Rates and Subsequent Metastatic Prostate Cancer Incidence in a National Healthcare System

ASTRO 2022: Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology

ASTRO 2022: Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer (EXTEND): A Multicenter, Randomized Phase II Trial

1
2
3